Immune-Related Gene Signatures to Predict the Effectiveness of Chemoimmunotherapy in Triple-Negative Breast Cancer Using Exploratory Subgroup Discovery

SIMPLE SUMMARY: Chemoimmunotherapy combinations have transformed the treatment landscape for patients with triple-negative breast cancer (TNBC). However, the discovery of immune-related biomarkers is needed to optimally identify patients requiring the addition of immune-checkpoint inhibitors (ICIs)...

Descripción completa

Detalles Bibliográficos
Autores principales: Kholod, Olha, Basket, William I., Mitchem, Jonathan B., Kaifi, Jussuf T., Hammer, Richard D., Papageorgiou, Christos N., Shyu, Chi-Ren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9735620/
https://www.ncbi.nlm.nih.gov/pubmed/36497286
http://dx.doi.org/10.3390/cancers14235806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9735620/
https://www.ncbi.nlm.nih.gov/pubmed/36497286
http://dx.doi.org/10.3390/cancers14235806

Ejemplares similares